Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human HDAC8 Protein, N-His

Catalog #:   YHJ51301 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: Q9BY41
Protein length: Met1-Val377
Overview

Catalog No.

YHJ51301

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Met1-Val377

Predicted molecular weight

44.07 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

Q9BY41

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

HDAC8, Histone deacetylase 8, HD8, HDACL1

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human HDAC8 protein
References

Novel Heterocyclic Compounds Exhibit Potent Antileukemic Activity through Selective Induction of Apoptosis and HDAC8 Interaction in AML Cells., PMID:40491377

Synergistic HDAC4/8 Inhibition Sensitizes Osteosarcoma to Doxorubicin via pAKT/RUNX2 Pathway Modulation., PMID:40332124

Conversion of Ku80 K568 crotonylation to SUMOylation facilitates DNA non-homologous end joining and cancer radioresistance., PMID:40254688

The combined effects of HSV-1 glycoprotein D and aluminum hydroxide on human neuroblastoma cells: Insights into oxidative DNA damage, apoptosis, and epigenetic modifications., PMID:40112954

Phosphatase PHLPP1 is an alveolar-macrophage-intrinsic transcriptional checkpoint controlling pulmonary fibrosis., PMID:40085643

Genetically Encoded Fluorescent and Bioluminescent Probes for HDAC8., PMID:40045791

CK2B Induces CD8+ T-Cell Exhaustion through HDAC8-Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer., PMID:40013761

Fluorogenic selective detection of Zn2+ using a pyrazole-ortho-vanillin conjugate: insights from DFT, molecular docking, bioimaging and anticancer applications., PMID:39950208

Binding mechanism and distant regulation of histone deacetylase 8 by PCI-34051., PMID:39939814

lncRNA ENST000000454471 promotes lung adenocarcinoma progression and tumor immune escape: Protein structure and biological functions of histone deacetylase 8., PMID:39909272

Investigation of All Disease-Relevant Lysine Acetylation Sites in α-Synuclein Enabled by Non-canonical Amino Acid Mutagenesis., PMID:39896484

Hypoxia-induced conversion of sensory Schwann cells into repair cells is regulated by HDAC8., PMID:39779705

Combinatorial phenethyl isothiocyanate and withaferin A targets multiple epigenetics pathways to inhibit MCF-7 and MDA-MB-231 human breast cancer cells., PMID:39707321

A pilot study on the efficacy of a telomerase activator in regulating the proliferation of A375 skin cancer cell line., PMID:39704853

Genome Instability and Senescence Are Markers of Cornelia de Lange Syndrome Cells., PMID:39682772

Repurposed drugs as histone deacetylase 8 inhibitors: Implications in cancer and neuropathological conditions., PMID:39611171

Histone deacetylase 8 in focus: Decoding structural prerequisites for innovative epigenetic intervention beyond hydroxamates., PMID:39608552

Repurposing of DrugBank molecules as dual non-hydroxamate HDAC8 and HDAC2 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics studies., PMID:39604351

YAK577 Attenuates Cardiac Remodeling and Fibrosis in Isoproterenol-Infused Heart Failure Mice by Downregulating MMP12., PMID:39601396

Lysine deacetylase inhibitors have low selectivity in cells and exhibit predominantly off-target effects., PMID:39482806

Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Improve the Intestinal Epithelial Barrier to Relieve Colitis., PMID:39440960

Knockout of histone deacetylase 8 gene in breast cancer cells may alter the expression pattern of the signaling molecules., PMID:39437892

dCas9-HDAC8-EGFP fusion enables epigenetic editing of breast cancer cells by H3K9 deacetylation., PMID:39437453

Combined HDAC8 and checkpoint kinase inhibition induces tumor-selective synthetic lethality in preclinical models., PMID:39436709

HDAC8 as a target in drug discovery: Function, structure and design., PMID:39427514

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders., PMID:39423771

Discovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity., PMID:39357770

Inhibition of HDAC8 mitigates AKI by reducing DNA damage and promoting homologous recombination repair., PMID:39317961

ZNF521 promotes acute myeloid leukemogenesis by suppressing the expression and acetylation of SMC3., PMID:39309877

Global isonicotinylome analysis identified SMAD3 isonicotinylation promotes liver cancer cell epithelial-mesenchymal transition and invasion., PMID:39286495

N-Myc and STAT Interactor is an Endometriosis Suppressor., PMID:39125716

N-(2-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Induces Apoptosis and Cell Cycle Arrest in Breast Cancer Cells, Decreasing GPER Expression., PMID:39124913

A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013-present)., PMID:39121339

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy against Breast Cancer., PMID:39110628

Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines., PMID:39097736

Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors., PMID:39089850

HDAC8 Enhances the Function of HIF-2α by Deacetylating ETS1 to Decrease the Sensitivity of TKIs in ccRCC., PMID:39073752

Reversible acetylation of HDAC8 regulates cell cycle., PMID:39043961

Crucial Structural Understanding for Selective HDAC8 Inhibition: Common Pharmacophores, Molecular Docking, Molecular Dynamics, and Zinc Binder Analysis of selective HDAC8 inhibitors., PMID:39039678

Histone deacetylase 8 promotes innate antiviral immunity through deacetylation of RIG-I., PMID:39035358

Chitosan-enclosed SLN improved SV-induced hepatocellular cell carcinoma death by modulation of IQGAP gene expression, JNK, and HDAC activities., PMID:39023688

Design and evaluation of nanoscale materials with programmed responsivity towards epigenetic enzymes., PMID:39021201

Unveiling the PDK4-centered rituximab-resistant mechanism in DLBCL: the potential of the "Smart" exosome nanoparticle therapy., PMID:39004737

Synthesis and cytotoxic evaluation of heterocyclic compounds by vinylic substitution of ketene dithioacetals., PMID:38997237

Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8., PMID:38949959

Rapid Determination of Kinetic Constants for Slow-Binding Inhibitors and Inactivators of Human Histone Deacetylase 8., PMID:38891780

Discovery of a dual-target DYRK2 and HDAC8 inhibitor for the treatment of hepatocellular carcinoma., PMID:38889633

Unveiling critical structural features for effective HDAC8 inhibition: a comprehensive study using quantitative read-across structure-activity relationship (q-RASAR) and pharmacophore modeling., PMID:38871969

The Importance of Structural Water in HDAC8 for Correct Binding Pose Applied for Drug Design of Anticancer Molecules., PMID:38835122

Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051., PMID:38782078

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human HDAC8 Protein, N-His [YHJ51301]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only